Does Creatine Help the APOE4 Brain? What the Clinical Trials Show

Hi Phoenix friend,

Creatine for Your Brain: What the Human Trials Actually Show

Fifteen dollars. One dose. In a randomized controlled trial it sharpened people's thinking in about four hours. Then researchers gave it to people who already had Alzheimer's, and the creatine inside their brains went up 11 percent.

This is the full written synthesis of creatine for the APOE4 brain. Prefer to watch? Here's the 31-minute deep dive on YouTube (studies on screen, full stories, every number explained):

Introduction

Creatine has spent decades in gym bags. Until very recently, almost nobody asked what it does inside the brain.

Then a team in Germany ran a sleep-deprivation RCT. Then Kansas researchers ran the first human trial of creatine in Alzheimer's patients. And the meta-analyses started pulling the pieces together.

Here is what this synthesis covers: the actual trial results (including the clean null), why APOE4 carriers have a specific early reason to care, how the chemistry works, what the trials actually used dose-for-dose, and the one number on your next blood test that will look alarming and isn't.

The through-line: the earliest APOE4 fingerprint isn't a memory problem. It's a brain energy problem. And creatine is a brain energy tool. [6]

What the Trials Found

Two anchor human studies define the current evidence base.

The first is a 2024 double-blind randomized crossover RCT from Germany (n=15) [1]. Researchers kept healthy adults awake for roughly 21 hours. One night: a single high dose of creatine (0.35 g/kg bodyweight). The other: placebo. On the creatine night, cognition, processing speed, and vigilance held up measurably better. [1] Peak effect came around four hours post-dose, lasting up to nine. [1] The authors wrote that this "revises the established assumption that creatine supplementation only works over a longer period." [1]

Fifteen people, young, and sleep-deprived. Not the final word. But it proved one thing cleanly: creatine can shift brain energy chemistry fast.

The second is the CABA pilot (NCT05383833), published 2025 [2]. Twenty Alzheimer's patients, 65% APOE4 carriers, took 20 g/day for eight weeks. Brain total creatine rose an average of 11%, going up in 85% of participants. [2] Several cognitive scores improved. A companion bioenergetics paper from the same 20 patients found cellular ATP and ADP rose after eight weeks. [3]

The giant asterisk: CABA had no control group. The authors themselves wrote that the design "prevents the ability to make conclusions of efficacy" and that they "urge caution when interpreting these results." [2] The companion bioenergetics study adds the same caution. [3] This is a feasibility signal. An early-signal study that earns a real RCT. Nothing more.

💡 KEY INSIGHT: Creatine demonstrably gets into the brain that needs it most. The CABA pilot isn't proof of efficacy, but an 11% rise in brain creatine in Alzheimer's patients, via an uncontrolled pilot, is exactly the kind of signal that justifies a larger controlled trial.

Memory and Speed, Not General Intelligence

Zoom out to the pooled evidence and the picture clarifies, but stays specific.

A 2024 meta-analysis of 16 randomized trials (~492 participants) found creatine improved memory at moderate certainty and processing speed and attention time at low certainty. [4] Global cognition and executive function did not reach significance. This is not a broad "makes you smarter" supplement.

Then the age finding. A second meta-analysis of 8 RCTs in healthy individuals found the memory effect was far larger in older adults. Effect size in the 66-76 age group: 0.88. In younger people (ages 11-31): 0.03. [5] Older adults tend to run lower on baseline brain creatine, which means more room to gain.

For once, being older is the advantage.

⚠️ CAVEAT: Moderate and low certainty ratings reflect real uncertainty. Meaningful heterogeneity exists across studies, and most trials enrolled healthy adults, not people in the early stages of neurodegenerative disease. [4] Take the effect sizes as a directional signal, not a guaranteed personal outcome.

Why APOE4 Carriers Have a Specific Reason to Care

Here is what rarely gets explained alongside an APOE4 result.

Cerebral glucose hypometabolism, the brain pulling in and burning less glucose, appears in young, cognitively normal APOE4 carriers decades before any symptom. [6] This is observed in human cohort data.

APOE4 appears to push brain metabolism toward a less efficient route: burning glucose to lactate instead of fully oxidizing it for ATP. A 2021 study using a human observational cohort (alongside mouse and cell data to probe the mechanism) found this pattern in young female carriers, what the researchers called "a Warburg-like endophenotype that is observable in young females decades prior to clinically manifest AD." [6] The exact mechanisms of how APOE4 affects brain energy metabolism are still being worked out. [7]

Separately, a 2018 human imaging study found brain high-energy phosphate metabolism is measurably altered in mild Alzheimer's: phosphocreatine elevated in regions of early degeneration, pointing to disrupted energy handling even early in the disease. [8]

Creatine sits directly inside this pathway. If the brain can't efficiently extract energy from glucose, a supplement that buffers ATP demand directly is exactly the kind of low-cost lever worth testing.

⚠️ CAVEAT: No creatine RCT has been powered on APOE4 carriers as a prevention endpoint. The APOE4 relevance is mechanistic. The bioenergetic deficit is established. That creatine specifically buffers it in humans remains a compelling hypothesis under active investigation, not a proven carrier intervention.

How the Battery Works (and Why Two Doses Both Make Sense)

Your brain cells run on ATP. When a neuron fires hard, it burns ATP to ADP faster than the cell can rebuild it from scratch.

Phosphocreatine steps in immediately. Via the enzyme creatine kinase, it donates a phosphate group back to ADP and regenerates ATP on the spot. More creatine stored means a bigger, faster energy reserve. [10] That is the rechargeable battery, and it's the actual chemistry, not a metaphor.

So why did one study use 0.35 g/kg once while another used 20 g/day for two months?

The blood-brain barrier has limited creatine transporters (SLC6A8). Brain creatine rises slowly. The CABA protocol patiently built up brain stores over weeks, which is exactly what the 11% MRI spectroscopy rise captured. [2] The single large dose in the sleep RCT works differently: under acute high demand, a big bolus can briefly push more uptake right when demand is spiking. Two mechanisms, same fuel.

Daily dosing fills the tank. A single large dose is an emergency top-up under stress. Two completely different jobs.

What to Actually Do (Including the Lab Number That Will Look Wrong)

The trials used specific doses. Referencing them, not guessing at them, is the point.

• CABA Alzheimer's pilot: 20 g/day (two 10 g doses) for 8 weeks

• Sleep deprivation RCT: a single 0.35 g/kg dose

• Most everyday brain research: 3-5 g/day

Form across all of it: plain creatine monohydrate. Skip the "HCL" or "buffered" premium versions. No good evidence they outperform the cheap version.

Stack it with resistance training. A 2026 narrative review called creatine plus structured exercise "a safe and promising strategy to counteract age-related declines in both physical and cognitive functions," with cognitive gains strongest in people with lower baseline creatine. [11] Muscle is the body's biggest creatine reservoir. Exercise drives brain energy metabolism independently. You are feeding the battery from both ends at once.

✅ ACTION STEP: The one practical thing you need to know before your next blood test: creatine breaks down to creatinine, a waste product that appears on your metabolic panel. In CABA, creatinine rose from 0.94 to 1.25 mg/dL while the rest of the panel stayed stable. [2] Phoenix optimal creatinine is 0.8-1.1 mg/dL for males and 0.7-0.9 mg/dL for females. A rise on creatine is an expected lab artifact, not kidney damage. Know that before you panic on the phone with your doctor.

The Honest Part: What Creatine Doesn't Show

One clean trial found nothing.

A 2013 double-blind, placebo-controlled 24-week RCT in healthy older women (Alves et al.) tested creatine with and without strength training. Neither combination improved cognition on any measure. [9] This is in exactly the older-adult population the meta-analyses say should benefit most.

Both things are true at the same time. That's what real science looks like before it settles.

In late 2025, the EVOKE program tested semaglutide in nearly 4,000 people. It moved biomarkers and still failed to slow cognition in carriers who felt fine. The lesson for creatine is the same: strong short-term data or biomarker signals do not equal long-term clinical benefit.

And those "creatine clears amyloid" headlines? Mouse models, not human trials. [12] Don't let rodent data get handed to you as a human promise.

The honest framing: creatine is a cheap, low-risk, well-tolerated bet on a real problem, while bigger controlled trials run. That's a smaller claim than the hype. It's far more defensible.

Key Takeaways

💡 Quick-Start Protocol (This Week):

1. Buy creatine monohydrate. It's the cheapest and most studied form. Skip anything labeled "HCL" or "buffered."

2. Consistency beats heroics. The trials that built brain stores used daily dosing over weeks. One scoop isn't the mechanism.

3. Stack with resistance training. Creatine plus exercise beats either one alone for both body and brain. [11]

4. Flag your doctor on creatinine. A rise on your blood panel after starting creatine is expected and benign, not kidney damage. Read it against your APOE4-context range.

5. Calibrate your expectations. Memory and processing speed are the domains with real evidence. Not global cognition, not a cure. A specific, low-cost asymmetric bet while the field catches up.

Track It in Phoenix Supplements and Bloodwork

When your creatinine ticks up at your next blood draw, Phoenix Bloodwork shows you your range in the context of supplementation, so a predictable rise doesn't read as a crisis.

Pull up creatine in the Phoenix Supplements Library to see the evidence grade and what other APOE4 carriers are actually reporting. Not internet threads. People with your genotype. Log it in My Stack. Upload your bloodwork. Let the pattern tell you something real instead of guessing in isolation.

Genes set the table. You decide what you bring to it. Creatine is one of the cheapest dishes you can bring right now.

Not part of Phoenix yet? Join here!

Cheers,

Kevin

Sources

Match each numbered citation in the article to the same number below. Select View source to open the original paper or trial record.

1. Gordji-Nejad A, Matusch A, Kleedoerfer S, et al. (2024). Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Scientific Reports. View source

2. Smith AN, Choi IY, Lee P, et al. (2025). Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition. Alzheimer's & Dementia: Translational Research & Clinical Interventions. View source

3. Taylor MK, Smith AN, Choi IY, et al. (2026). Bioenergetic data from a creatine monohydrate pilot trial in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions. View source

4. Xu C, Bi S, Zhang W, Luo L. (2024). The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition. View source

5. Prokopidis K, Giannos P, Triantafyllidis KK, et al. (2023). Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews. View source

6. Farmer BC, Williams HC, Devanney NA, et al. (2021). APOE4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis. Molecular Neurodegeneration. View source

7. Budny V, Ruminot I, Wybitul M, et al. (2025). Fueling the brain: the role of apolipoprotein E in brain energy metabolism and its implications for Alzheimer's disease. Translational Psychiatry. View source

8. Rijpma A, van der Graaf M, Meulenbroek O, et al. (2018). Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional 31P MR spectroscopic imaging study. NeuroImage: Clinical. View source

9. Alves CRR, Merege Filho CAA, Benatti FB, et al. (2013). Creatine supplementation associated or not with strength training upon emotional and cognitive measures in older women: a randomized double-blind study. PLoS One. View source

10. Taylor MK, Burns JM, Choi IY, et al. (2024). Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer's disease. Pilot and Feasibility Studies. View source

11. Li N. (2026). Creatine supplementation and exercise in aging: a narrative review of the muscle-brain axis and its impact on cognitive and physical health. Frontiers in Nutrition. View source

12. Smith AN, Morris JK, Carbuhn AF, et al. (2023). Creatine as a Therapeutic Target in Alzheimer's Disease. Current Developments in Nutrition. [View source